- Home
- IIIV vs VALN Comparison
IIIV vs VALN Comparison
Compare IIIV & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- VALN
- Stock Information
- Founded
- IIIV 2012
- VALN 2012
- Country
- IIIV United States
- VALN France
- Employees
- IIIV N/A
- VALN N/A
- Industry
- IIIV EDP Services
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IIIV Technology
- VALN Health Care
- Exchange
- IIIV Nasdaq
- VALN Nasdaq
- Market Cap
- IIIV 720.4M
- VALN 777.9M
- IPO Year
- IIIV 2018
- VALN 2021
- Fundamental
- Price
- IIIV $30.78
- VALN $8.93
- Analyst Decision
- IIIV Buy
- VALN Strong Buy
- Analyst Count
- IIIV 6
- VALN 4
- Target Price
- IIIV $34.33
- VALN $15.75
- AVG Volume (30 Days)
- IIIV 182.1K
- VALN 124.3K
- Earning Date
- IIIV 08-07-2025
- VALN 11-06-2025
- Dividend Yield
- IIIV N/A
- VALN N/A
- EPS Growth
- IIIV N/A
- VALN N/A
- EPS
- IIIV 5.56
- VALN N/A
- Revenue
- IIIV $248,271,000.00
- VALN $230,566,060.00
- Revenue This Year
- IIIV N/A
- VALN $14.76
- Revenue Next Year
- IIIV $3.86
- VALN $24.11
- P/E Ratio
- IIIV $5.51
- VALN N/A
- Revenue Growth
- IIIV 25.08
- VALN 25.47
- 52 Week Low
- IIIV $20.42
- VALN $3.62
- 52 Week High
- IIIV $33.44
- VALN $12.25
- Technical
- Relative Strength Index (RSI)
- IIIV 52.24
- VALN 49.17
- Support Level
- IIIV $29.99
- VALN $8.33
- Resistance Level
- IIIV $31.20
- VALN $9.46
- Average True Range (ATR)
- IIIV 0.87
- VALN 0.35
- MACD
- IIIV -0.12
- VALN -0.13
- Stochastic Oscillator
- IIIV 56.43
- VALN 62.55
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.